Source:http://linkedlifedata.com/resource/pubmed/id/15645481
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
5
|
pubmed:dateCreated |
2005-5-5
|
pubmed:abstractText |
To determine the long-term efficacy of botulinum toxin (BTX) treatments, we analyzed longitudinal follow-up data on 45 patients (32 women; mean age, 68.8 years) currently followed in the Baylor College of Medicine Movement Disorders Clinic, who have received BTX treatments continuously for at least 12 years (mean 15.8 +/- 1.5 years). Their mean response rating after the last injection, based one a previously described scale 0-to-4 scale (0 = no effect; 4 = marked improvement) was 3.7 +/- 0.6 and the mean total duration of response was 15.4 +/- 3.4 weeks. Although the latency and total duration of the response to treatment have not changed over time, the peak duration of response (P < 0.005) and dose per visit (P < 0.0001) have increased since the initial visit. Furthermore, global rating (P < 0.02) and peak effect (P < 0.05) have improved. In total, 20 adverse events occurred in 16 of 45 (35.6%) patients after their initial visit and 11 adverse events in 10 of 45 (22.2%) patients at their most recent injection visit. Antibody (Ab) testing was carried out in 22 patients due to nonresponsiveness; blocking Abs were confirmed by the mouse protection assay in 4 of 22 (18%) patients. Of the Ab-negative patients, 16 resumed responsiveness after dose adjustments and 2 persisted as nonrespondents. Except for 1 patient, the 4 Ab-positive and the 2 clinical nonresponders are being treated with BTX-B. This longest reported follow-up of BTX injections confirms the long-term efficacy and safety of this treatment.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
May
|
pubmed:issn |
0885-3185
|
pubmed:author | |
pubmed:copyrightInfo |
Copyright 2005 Movement Disorder Society.
|
pubmed:issnType |
Print
|
pubmed:volume |
20
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
592-7
|
pubmed:dateRevised |
2010-11-18
|
pubmed:meshHeading |
pubmed-meshheading:15645481-Aged,
pubmed-meshheading:15645481-Antibodies,
pubmed-meshheading:15645481-Blepharoptosis,
pubmed-meshheading:15645481-Botulinum Toxins, Type A,
pubmed-meshheading:15645481-Deglutition Disorders,
pubmed-meshheading:15645481-Drug Administration Schedule,
pubmed-meshheading:15645481-Dystonia,
pubmed-meshheading:15645481-Female,
pubmed-meshheading:15645481-Hemifacial Spasm,
pubmed-meshheading:15645481-Humans,
pubmed-meshheading:15645481-Injections,
pubmed-meshheading:15645481-Male,
pubmed-meshheading:15645481-Middle Aged,
pubmed-meshheading:15645481-Muscle Weakness,
pubmed-meshheading:15645481-Neck Muscles,
pubmed-meshheading:15645481-Neuromuscular Agents,
pubmed-meshheading:15645481-Time Factors
|
pubmed:year |
2005
|
pubmed:articleTitle |
Long-term botulinum toxin efficacy, safety, and immunogenicity.
|
pubmed:affiliation |
Parkinson's Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, Texas 77030, USA.
|
pubmed:publicationType |
Journal Article,
Clinical Trial
|